Since we have found that hAT-MSCs could decrease the level of serum IgE in AD and this efficacy might result from the systemic regulation of allergic responses, we further investigated whether AT-MSCs could inhibit the allergic responses of B lymphocyte in vitro. This evidence concerns the gene IGHE and Alzheimer disease.